FDA clears Eisai’s insomnia drug Dayvigo

The FDA’s traditional last-minute flurry of approvals as the year heads to a close included Eisai’s Dayvigo, a new treatment for insomnia that is the first direct competition to Merck & Co’s Belsomra.